Pesquisas alternativas:
does develop » boys develop (Expandir a Pesquisa), loss develop (Expandir a Pesquisa), does developing (Expandir a Pesquisa)
develop them » develop type (Expandir a Pesquisa)
level theory » model theory (Expandir a Pesquisa)
dose devel » dose level (Expandir a Pesquisa), dose levels (Expandir a Pesquisa), dose novel (Expandir a Pesquisa)
devel ther » novel ther (Expandir a Pesquisa)
drug does » drug doses (Expandir a Pesquisa), drugs does (Expandir a Pesquisa), drug de (Expandir a Pesquisa)
drug dose » drug dosage (Expandir a Pesquisa)
does develop » boys develop (Expandir a Pesquisa), loss develop (Expandir a Pesquisa), does developing (Expandir a Pesquisa)
develop them » develop type (Expandir a Pesquisa)
level theory » model theory (Expandir a Pesquisa)
dose devel » dose level (Expandir a Pesquisa), dose levels (Expandir a Pesquisa), dose novel (Expandir a Pesquisa)
devel ther » novel ther (Expandir a Pesquisa)
drug does » drug doses (Expandir a Pesquisa), drugs does (Expandir a Pesquisa), drug de (Expandir a Pesquisa)
drug dose » drug dosage (Expandir a Pesquisa)
1
Por Zhang, Meijuan, Wang, Haiying, Zhao, Jinbing, Chen, Cong, Leak, Rehana K., Xu, Yun, Vosler, Peter, Gao, Yanqin, Zhang, Feng
Publicado em 2013
“... to induce therapeutic hypothermia have been established; however, most of them are not clinically feasible...”Publicado em 2013
Obter o texto integral
Obter o texto integral
Artigo
2
Por Park, Gab-jin, Bae, Soo Hyeon, Park, Wan-Su, Han, Seunghoon, Park, Min-Ho, Shin, Seok-Ho, Shin, Young G, Yim, Dong-Seok
Publicado no Drug Des Devel Ther (2017)
“...PURPOSE: A microdose drug–drug interaction (DDI) study may be a valuable tool for anticipating drug...”Publicado no Drug Des Devel Ther (2017)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
3
Por Wesnes, Keith A.
Publicado em 2000
“...This paper reviews the value and utility of measuring cognitive function in the development of new...”Publicado em 2000
Obter o texto integral
Obter o texto integral
Artigo
4
“... indicate that the polymer-bound drug does not diffuse into the muscle tissues. We feel that our findings...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
5
Por A. E. Karateyev
Publicado em 2013-12-01
Assuntos:
“...nonsteroidal anti-inflammatory drugs...”Publicado em 2013-12-01
Obter o texto integral
Artigo
6
“... approach “Design of Experiments (DoE)” as applicable to formulation development of microparticles...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
7
Por Wu, Jiasi, Hu, Yingfan, Xiang, Li, Li, Sheng, Yuan, Yi, Chen, Xiaomei, Zhang, Yan, Huang, Wenge, Meng, Xianli, Wang, Ping
Publicado no Front Pharmacol (2016)
“... against inflammatory abnormalities. Mutual reinforcement is one of the basic theories of traditional...”Publicado no Front Pharmacol (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
8
Por Takenaka, Yukinori, Fukumori, Tomoharu, Yoshii, Tadashi, Oka, Natsuo, Inohara, Hidenori, Kim, Hyeong-Reh Choi, Bresalier, Robert S., Raz, Avraham
Publicado em 2004
Assuntos:
“...Cell Growth and Development...”Publicado em 2004
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
9
Por Yildirim, Oktay, Gottwald, Matthias, Schüler, Peter, Michel, Martin C.
Publicado no Front Pharmacol (2016)
“...Drug development faces the double challenge of increasing costs and increasing pressure on pricing...”Publicado no Front Pharmacol (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
10
Por Barker, David J., Bercovicz, Danielle, Servilio, Lisa C., Simmons, Steven J., Ma, Sisi, Root, David H., Pawlak, Anthony P., West, Mark O.
Publicado em 2013
“...Human self-reports often indicate that changes in mood are a major contributor to drug relapse...”Publicado em 2013
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
11
Por Mingote, Susana, Masson, Justine, Gellman, Celia, Thomsen, Gretchen M., Lin, Chyuan-Sheng, Merker, Robert J., Gaisler-Salomon, Inna, Wang, Yvonne, Ernst, Rachel, Hen, René, Rayport, Stephen
Publicado no Front Syst Neurosci (2016)
“...Genetic pharmacotherapy is an early drug development strategy for the identification of novel CNS...”Publicado no Front Syst Neurosci (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
12
“...BACKGROUND: Less is known about mass drug administration [MDA] for neglected tropical diseases...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
13
Por Song, Chull S., Moses, Harold L., Rosenthal, Alan S., Gelb, Nancy A., Kappas, Attallah
Publicado em 1971
“... inducers of hepatic ALAS does, however, develop in neonatal animals so that by approximately 5–6 wk of age...”Publicado em 1971
Obter o texto integral
Obter o texto integral
Artigo
14
“... to an antibiotic are also discussed. Lastly, the methods that have been developed for the identification...”
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
15
Por Lee, Jieon, Yoon, Seonghae, Shin, Donghoon, Han, HyeKyung, An, Hyungmi, Lee, Jongtae, Lim, Kyoung Soo, Yu, Kyung-Sang, Lee, Howard
Publicado em 2014
“... nomograms may be required in patients with IE, particularly for once-daily dosing. Therapeutic drug...”Publicado em 2014
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
16
Por Barbarash, Olga, Gruzdeva, Olga, Uchasova, Evgenya, Belik, Ekaterina, Dyleva, Yulia, Karetnikova, Victoria
Publicado no Drug Des Devel Ther (2015)
“..., resulted in a decrease in free fatty acid levels. The positive effect of low-dose atorvastatin (20 mg/day...”Publicado no Drug Des Devel Ther (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
17
Por Phansalkar, Shobha, Desai, Amrita A, Bell, Douglas, Yoshida, Eileen, Doole, John, Czochanski, Melissa, Middleton, Blackford, Bates, David W
Publicado em 2012
“...OBJECTIVE: To develop a set of high-severity, clinically significant drug–drug interactions (DDIs...”Publicado em 2012
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
18
Por Kim, Yo Han, Choi, Hee Youn, Noh, Yook-Hwan, Lee, Shi Hyang, Lim, Hyeong-Seok, Kim, Chin, Bae, Kyun-Seop
Publicado no Drug Des Devel Ther (2015)
“... and high blood pressure. The aim of this study was to investigate the dose proportionality...”Publicado no Drug Des Devel Ther (2015)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
19
Por Erturk, Ayse, Adnan Akdogan, Remzi, Parlak, Emine, Cure, Erkan, Cumhur Cure, Medine, Ozturk, Cinar
Publicado em 2014
“... transaminase (ALT) normalization at the end of 4 years. CONCLUSION: Increasing ETV dose from 0.5 mg to 1 mg...”Publicado em 2014
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo
20
Por Wang, Ying, Sun, Sheng-Gang, Zhu, Sui-Qiang, Liu, Chun-Feng, Liu, Yi-Ming, Di, Qing, Shang, Hui-Fang, Ren, Yan, Xiang, Wei, Chen, Sheng-Di
Publicado no Drug Des Devel Ther (2016)
“... for Parkinson’s disease (PD). A critical dose level above which a better benefit-to-harm ratio exists has not been...”Publicado no Drug Des Devel Ther (2016)
Obter o texto integral
Obter o texto integral
Obter o texto integral
Artigo